Literature DB >> 1373592

Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine.

K Mizuno1, Y Furuhashi, T Misawa, M Iwata, M Kawai, F Kikkawa, T Kano, Y Tomoda.   

Abstract

It has recently been reported that an immunosuppressive agent, cyclosporin A, shows a potent overcoming effect on multidrug resistance (MDR). We studied the presence of such a modulating effect of cyclosporin analogues and other immunosuppressive agents, FK506 and mizoribine, in human multidrug-resistant ovarian cancer cells (TAOV/A0.2). The intensity of the overcoming effect of cyclosporin analogues against adriamycin resistance was found to be in the other of cyclosporin D greater than A greater than C greater than H. It was found that cyclosporin D, which has relatively weak immunosuppressive activity, overcame adriamycin resistance in the multidrug-resistant ovarian cancer cells to a remarkable degree. On the other hand, it was found that FK506, a new potent immunosuppressant, could also distinctly modulate adriamycin-resistance. It was found that FK506 conferred chemosensitization upon adriamycin with reincreasing intracellular adriamycin accumulation in MDR cells which was far less than the parent strain. However, in the case of mizoribine, no modulation of drug resistance existed. Such modulation was not necessarily accompanied by immunosuppressive activity and the two functions were thought to be based on different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373592

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans.

Authors:  M Del Poeta; M C Cruz; M E Cardenas; J R Perfect; J Heitman
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Modulation of Multidrug Resistance in Cancer by Immunosuppresive Agents. Preclinical Studies.

Authors:  Adorján Aszalos
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

Review 3.  Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.

Authors:  M E Cardenas; M C Cruz; M Del Poeta; N Chung; J R Perfect; J Heitman
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 5.  New therapeutic approaches to hepatitis C virus.

Authors:  Naoya Sakamoto; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2009-05-21       Impact factor: 7.527

6.  Functional expression of P-glycoprotein in Saccharomyces cerevisiae confers cellular resistance to the immunosuppressive and antifungal agent FK520.

Authors:  M Raymond; S Ruetz; D Y Thomas; P Gros
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

7.  Evidence for the role of calcineurin in morphogenesis and calcium homeostasis during mycelium-to-yeast dimorphism of Paracoccidioides brasiliensis.

Authors:  Claudia B L Campos; Joao Paulo T Di Benedette; Flavia V Morais; Rafael Ovalle; Marina P Nobrega
Journal:  Eukaryot Cell       Date:  2008-09-05

8.  Photodynamic inactivation with acridine orange on a multidrug-resistant mouse osteosarcoma cell line.

Authors:  K Kusuzaki; G Minami; H Takeshita; H Murata; S Hashiguchi; T Nozaki; T Ashihara; Y Hirasawa
Journal:  Jpn J Cancer Res       Date:  2000-04

9.  A Mechanosensitive Channel Governs Lipid Flippase-Mediated Echinocandin Resistance in Cryptococcus neoformans.

Authors:  Chengjun Cao; Yina Wang; Seema Husain; Patricia Soteropoulos; Chaoyang Xue
Journal:  mBio       Date:  2019-12-10       Impact factor: 7.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.